Patients who took the drug had their number of sleep apnea episodes reduced by about half to nearly 60 percent compared to ...
U.S.-led international trials treating obstructive sleep apnea using type 2 diabetic medication may offer new hope for ...
A new study finds the popular obesity drug Zepbound may help treat sleep apnea, a dangerous disorder in which people struggle ...
Investigators also saw improvements in inflammation and BP, but effects on hard CVD outcomes await a larger RCT.
Eli Lilly on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in ...
An existing drug has shown it can significantly improve the quality of sleep for those suffering from obstructive sleep apnea (OSA), so much so that many trial participants were able to hang up their ...
Drugmaker Eli Lilly is hoping tirzepatide, sold as Mounjaro and Zepbound for diabetes and weight loss, will become the first ...
Researchers at the University of California San Diego School of Medicine and international collaborators have led a worldwide ...
Two new clinical trials showed that tirzepatide, a weight loss drug, significantly improved symptoms of obstructive sleep apnea in people with obesity.
They found that tirzepatide significantly reduced the apnea-hypopnea index (AHI), body weight, concentration of high-sensitivity C-reactive protein (hsCRP), hypoxic burden, and systolic blood pressure ...
Sleep apnea affects some 20 million Americans and can cause issues like snoring, brain fog and daytime sleepiness, as well as ...
Treating obstructive sleep apnea with a type 2 diabetes medication may offer new hope for sufferers of the sleep disorder, a ...